FibroGen Inc (FGEN)
0.3834
-0.01
(-1.69%)
USD |
NASDAQ |
Nov 26, 16:00
0.3834
0.00 (0.00%)
After-Hours: 20:00
FibroGen Revenue (TTM): 180.01M for Sept. 30, 2024
Revenue (TTM) Chart
Historical Revenue (TTM) Data
Date | Value |
---|---|
September 30, 2024 | 180.01M |
June 30, 2024 | 173.82M |
March 31, 2024 | 167.49M |
December 31, 2023 | 147.75M |
September 30, 2023 | 154.98M |
June 30, 2023 | 130.58M |
March 31, 2023 | 116.07M |
December 31, 2022 | 140.74M |
September 30, 2022 | 122.91M |
June 30, 2022 | 263.15M |
March 31, 2022 | 257.71M |
December 31, 2021 | 235.31M |
September 30, 2021 | 283.76M |
June 30, 2021 | 171.82M |
March 31, 2021 | 190.35M |
December 31, 2020 | 176.32M |
September 30, 2020 | 119.30M |
June 30, 2020 | 108.44M |
March 31, 2020 | 257.12M |
December 31, 2019 | 256.58M |
September 30, 2019 | 356.66M |
Date | Value |
---|---|
June 30, 2019 | 352.51M |
March 31, 2019 | 204.90M |
December 31, 2018 | 212.96M |
September 30, 2018 | 135.64M |
June 30, 2018 | 147.16M |
March 31, 2018 | 133.48M |
December 31, 2017 | 131.00M |
September 30, 2017 | 135.78M |
June 30, 2017 | 125.34M |
March 31, 2017 | 184.35M |
December 31, 2016 | 183.19M |
September 30, 2016 | 172.11M |
June 30, 2016 | 161.54M |
March 31, 2016 | 192.81M |
December 31, 2015 | 180.83M |
September 30, 2015 | 172.49M |
June 30, 2015 | 166.62M |
March 31, 2015 | 136.02M |
December 31, 2014 | 137.60M |
September 30, 2014 | 133.89M |
June 30, 2014 | 191.47M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (TTM) Range, Past 5 Years
108.44M
Minimum
Jun 2020
283.76M
Maximum
Sep 2021
182.71M
Average
172.82M
Median
Revenue (TTM) Benchmarks
Biomarin Pharmaceutical Inc | 2.753B |
Arbutus Biopharma Corp | 6.742M |
GlycoMimetics Inc | -- |
Cidara Therapeutics Inc | -- |
Cue Biopharma Inc | 9.532M |